Cargando…

Changes in bone quality after switching from a TDF to a TAF based ART: A pilot randomized study

BACKGROUND: The impact of tenofovir disoproxil fumarate (TDF) antiretroviral (ART) regimens on bone health has been characterized mostly by bone mineral density (BMD), but recently also by bone quality (BQ). The aim of this pilot study is to assess the changes in BMD and BQ after switch from TDF to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soldado-Folgado, Jade, Rins-Lozano, Oriol, Arrieta-Aldea, Itziar, Gonzále-Mena, Alicia, Cañas-Ruano, Esperanza, Knobel, Hernando, Garcia-Giralt, Natalia, Güerri-Fernández, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083312/ https://www.ncbi.nlm.nih.gov/pubmed/37051195 http://dx.doi.org/10.3389/fendo.2023.1076739

Ejemplares similares

An Abnormal Inflammatory Pattern Associated with Long-Term Non-Progression of HIV Infection Impacts Negatively on Bone Quality
por: Soldado-Folgado, Jade, et al.
Publicado: (2022)

337. Switching from TDF to TAF: Missed Opportunities for Statin Use in HIV
por: Mallon, Patrick, et al.
Publicado: (2019)

Weight gain before and after switch from TDF to TAF in a U.S. cohort study
por: Mallon, Patrick WG, et al.
Publicado: (2021)

Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides
por: Mallon, Patrick W G, et al.
Publicado: (2021)

Factors associated to neurocognitive impairment in older adults living with HIV
por: Gutierrez-San-Juan, Júlia, et al.
Publicado: (2022)

979. BMI and ASCVD Risk Score Changes in Virologically Suppressed Patients with HIV Switching from TDF to TAF Containing ART
por: Schafer, Jason J, et al.
Publicado: (2019)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
por: Squillace, Nicola, et al.
Publicado: (2020)

995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline
por: Campbell, Thomas, et al.
Publicado: (2020)

Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction—A Prospective Cohort Study
por: Surial, Bernard, et al.
Publicado: (2020)

828. Short- and Long-Term Metabolic Changes in Virologically Suppressed Patients Switching from TDF to TAF Containing Antiretroviral Therapy
por: Schafer, Jason J, et al.
Publicado: (2021)

1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial
por: Wohl, David, et al.
Publicado: (2019)

Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
por: Thimm, Matthew A., et al.
Publicado: (2022)

LB-7. Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)
por: Sax, Paul, et al.
Publicado: (2020)

1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial
por: Mills, Anthony, et al.
Publicado: (2019)

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Wiriyatanakorn, Sirichai, et al.
Publicado: (2019)

855. Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis: A Real-World Evidence Analysis in the United States
por: Tao, Li, et al.
Publicado: (2021)

ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study
por: Podzamczer, Daniel, et al.
Publicado: (2014)

A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
por: Gomez, Mario, et al.
Publicado: (2018)

Taf2 mediates DNA binding of Taf14
por: Klein, Brianna J., et al.
Publicado: (2022)

Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV
por: Munderi, Paula, et al.
Publicado: (2019)

Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial
por: Curran, Adrian, et al.
Publicado: (2020)

Correction to: A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017
por: Gomez, Mario, et al.
Publicado: (2018)

Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study
por: Martínez, E, et al.
Publicado: (2010)

A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination
por: Sax, Paul E, et al.
Publicado: (2017)

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years
por: Gazzard, Brian, et al.
Publicado: (2014)

TDF (Theoretical Domain Framework): how inclusive are TDF domains and constructs compared to other tools for assessing barriers to change?
por: Sarmast, Hamideh, et al.
Publicado: (2014)

318. Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) in Hispanic/Latinx and Black Participants: Efficacy, Bone and Renal Safety Results from a Pooled Analysis of 7 Clinical Trials
por: DeJesus, Edwin, et al.
Publicado: (2019)

Cytoplasmic TAF2–TAF8–TAF10 complex provides evidence for nuclear holo–TFIID assembly from preformed submodules
por: Trowitzsch, Simon, et al.
Publicado: (2015)

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera(®)). Efficacy and safety analysis. GeSida Study 8114
por: Pérez-Hernández, Isabel A, et al.
Publicado: (2014)

Identification of a Small TAF Complex and Its Role in the Assembly of TAF-Containing Complexes
por: Demény, Màté A., et al.
Publicado: (2007)

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
por: Hagins, D, et al.
Publicado: (2018)

2508. Virologic Suppression in Patients Switched to BIC/TAF/FTC with Baseline NRTI and/or INSTI Resistance
por: Natali, Kayla M, et al.
Publicado: (2019)

Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains
por: Bouché, Léa, et al.
Publicado: (2017)

No Emergent Resistance in HIV-1 Infected Virologically-Suppressed Subjects Who Switched to R/F/TAF
por: Porter, Danielle, et al.
Publicado: (2017)

A Randomized Clinical Trial of Transgender Women Switching to B/F/TAF: The (mo)BETTA Trial
por: Lake, Jordan E, et al.
Publicado: (2023)

Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study
por: Giacomelli, Andrea, et al.
Publicado: (2021)

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis
por: Stellbrink, Hans-Juergen, et al.
Publicado: (2014)

Architecture of TAF11/TAF13/TBP complex suggests novel regulation properties of general transcription factor TFIID
por: Gupta, Kapil, et al.
Publicado: (2017)

Deletion of taf1 and taf5 in zebrafish capitulate cardiac and craniofacial abnormalities associated with TAFopathies through perturbations in metabolism
por: Leid, Jamison, et al.
Publicado: (2023)

Development and Validation of a Risk Score for Predicting Non-Adherence to Antiretroviral Therapy
por: Acin, Pablo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sumv9ku7cn7tt836t261ijes7g